A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.

OBJECTIVE To determine, in stage IV non-small-cell lung cancer (NSCLC), if the combination of gemcitabine-a new active drug-with ifosfamide (IG) or with the cisplatin-carboplatin association (CCG) will improve survival (primary end point) in comparison with a first-generation regimen, cisplatin-carboplatin-ifosfamide (CCI). PATIENTS AND METHODS A total of 284 chemotherapy-naïve patients with metastatic NSCLC were randomised. Four were ineligible and 16 were not assessable for responses. Cisplatin was given at 60 mg/m2 on day 1, carboplatin AUC 3 mg.min/ml on day 1, ifosfamide 4.5 g/m2 on day 1 and gemcitabine 1 g/m2 on days 1, 8 and 15. Courses were repeated every 4 weeks. Response was assessed after three courses and chemotherapy was continued in responding patients until best response. There were 94 eligible patients in the CCI arm, 92 in CCG and 94 in the IG arm. RESULTS The objective response rates for CCI, CCG and IG were 23% [95% confidence interval (CI) 15% to 32%], 29% (95% CI 20% to 39%) and 25% (95% CI 16% to 33%), respectively ( P = 0.61). Median survival time was 24, 34 and 30 weeks, respectively (P = 0.20). One-year survival was 23, 33 and 35%, and 2-year survival was 11, 14 and 17%, respectively. In some subgroups (older patients, women), there was a significant survival advantage for CCG and IG compared with CCI. Toxicity was tolerable: severe alopecia was less frequent in the CCG arm, and IG was associated with significantly more thrombopenia while CCG was associated with more leucopenia. CONCLUSION In stage IV NSCLC, treatment with regimens including the new drug gemcitabine were associated with a better but not statistically significant observed survival compared with a classical first-generation cisplatin-containing regimen. The non-platinum combination of gemcitabine was as effective as its combination with platinum.

[1]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[2]  J. Lafitte,et al.  The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature , 2001, British Journal of Cancer.

[3]  R. Rosell,et al.  Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (gv/iv) in advanced non-small cell lung cancer (NSCLC): final results of a Spanish lung cancer group phase III trial (GEPC/98-02) , 2001 .

[4]  E. Smit,et al.  An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer , 2001 .

[5]  J. Lafitte,et al.  Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer , 2000, British Journal of Cancer.

[6]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Barni,et al.  Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Berghmans,et al.  Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: two pilot studies. , 1999, Anticancer Research.

[9]  R. Souhami,et al.  Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Paesmans,et al.  Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. , 1999, Anticancer research.

[11]  J. Lafitte,et al.  A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. , 1999, European journal of cancer.

[12]  C. Sotiriou,et al.  Best supportive care or chemotherapy for stage IV non-small cell lung cancer , 1999 .

[13]  A. Carrato,et al.  Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Lafitte,et al.  Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. , 1998, Lung cancer.

[15]  G. Giaccone,et al.  Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Lafitte,et al.  Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Stahel,et al.  Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Whang‐Peng,et al.  Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Bianco,et al.  Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. , 1996, British Journal of Cancer.

[20]  M. Paesmans,et al.  Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[22]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Crinò,et al.  Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Paesmans,et al.  A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer , 1994 .

[25]  M. Paesmans,et al.  A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. , 1994, Lung cancer.

[26]  J. Sculier,et al.  Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Crinò,et al.  Cisplatin (CDDP)-etoposide VS DCCP-mitomycin-vindesine VS CDDP-mitomycin-iphosphamide in advanced non small cell lung cancer (NSCLC). A prospective randomized trial of the Italian oncology group for clinical research. (GOIRC) , 1993 .

[28]  J. Sculier,et al.  CHIMIOTHERAPIE DES CANCERS BRONCHIQUES NON A PETITES CELLULES. META-ANALYSE DE LA LITTERATURE EN FONCTION DE L'EXTENSION DE LA MALADIE , 1991 .

[29]  M. Paesmans,et al.  [Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease]. , 1991, Revue des maladies respiratoires.

[30]  J. Sculier,et al.  A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michael J. Campbell,et al.  Statistical tables for the design of clinical trials , 1987 .